MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab
30 nov. 2020 16h30 HE
|
MacroGenics, Inc.
MacroGenics accesses EVERSANA’s full suite of commercial services for which both parties share expensesEVERSANA may earn revenue share payments over five years subject to predefined capMacroGenics’...
MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte
30 nov. 2020 07h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Participate in Upcoming Investor Conferences
09 nov. 2020 17h00 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Provides Update on Corporate Progress and Third Quarter 2020 Financial Results
04 nov. 2020 16h01 HE
|
MacroGenics, Inc.
ROCKVILLE, Md., Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Flotetuzumab and Tebotelimab Presentations at the ASH Annual Meeting 2020
04 nov. 2020 14h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Date of Third Quarter 2020 Financial Results Conference Call
28 oct. 2020 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Oct. 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Flotetuzumab Publication in Blood Advances
15 oct. 2020 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Oct. 15, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics
23 sept. 2020 07h15 HE
|
MacroGenics, Inc.
Manuscript describes preclinical development of MGC018Phase 1 dose expansion trial evaluating MGC018 in patients with mCRPC, TNBC and NSCLC is currently recruiting patients ROCKVILLE, MD,...
MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood
22 sept. 2020 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Sept. 22, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte
21 sept. 2020 07h30 HE
|
MacroGenics, Inc.
$15 Million milestone triggered by initiation of Phase 3 clinical trial in NSCLC by Incyte ROCKVILLE, MD, Sept. 21, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage...